Natalie Wynn, APRN
Nurse Practitioner · Las Vegas, NVNPI 1407487077
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,268 of the $6,068 with a category attached, or 86.8%. It is spread thinly across 33 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,091 and has fallen 75.4% since, to $513 in 2024. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $32.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Biohaven Pharmaceuticals, Inc.$979
- Amgen$480
- Lilly USA, LLC$428
- AstraZeneca$412
- plus $2K from 27 others
What the payments were for
- Consulting fees$80013%
- Food & beverage$5,26887%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $1,120 |
| AbbVie | 32 | $1,117 |
| Biohaven Pharmaceuticals, Inc. | 5 | $979 |
| Amgen(2 entities) | 15 | $480 |
| Lilly USA, LLC | 20 | $428 |
| AstraZeneca | 10 | $412 |
| Bayer | 6 | $329 |
| Pfizer | 9 | $141 |
| ANI Pharmaceuticals, Inc. | 4 | $115 |
| Masimo Corporation | 1 | $115 |
| Dexcom, Inc. | 6 | $101 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $89 |
| Lundbeck LLC | 3 | $84 |
| Gilead | 4 | $73 |
| Hologic Sales And Service, LLC | 3 | $49 |
| Antares Pharma, Inc. | 3 | $48 |
| Astellas Pharma US Inc | 2 | $47 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $37 |
| Mylan Specialty L.p. | 1 | $31 |
| Viiv Healthcare Company | 1 | $24 |
| Bioventus LLC | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| GSK | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,068 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $41,775 |
| MounjaroTirzepatide | 18 | $26,182 |
| JardianceEmpagliflozin | 17 | $24,469 |
| RybelsusSemaglutide | 11 | $23,726 |
| FarxigaDapagliflozin Propanediol | 19 | $22,716 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,361 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,885 |
| Atorvastatin Calcium | 137 | $1,610 |
| Rosuvastatin Calcium | 49 | $1,255 |
| Duloxetine Hcl | 16 | $715 |
| Tizanidine Hcl | 23 | $593 |
| Metformin Hcl | 77 | $579 |
| Amlodipine Besylate | 78 | $575 |
| Omeprazole | 38 | $568 |
| Metoprolol Succinate | 34 | $563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,120 | $65,50145 claims |
| Lilly USA, LLCMounjaro | $428 | $26,18218 claims |
| Boehringer IngelheimJardiance | $37 | $24,46917 claims |
| AstraZenecaFarxiga | $412 | $22,71619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Las Vegas
- Melanie SpeedLas Vegas$80K
- Shelley MilesLas Vegas$34K
- Nasslynne LenzLas Vegas$32K
- Shannon SouthwickLas Vegas$32K
- Bonnie KwanLas Vegas$30K
- Amanda RalphLas Vegas$26K
- Teodoro AgtayLas Vegas$25K
- Katherine WhitmireLas Vegas$18K
- Jennifer WalshLas Vegas$18K
- Andrew VolinLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.